<p class="first" id="d2715365e142">Ectopic expression of netrin-1 has been validated
in several cancers including non-small
cell lung cancer (NSCLC). Recent research confirms the critical role of netrin-1 in
NSCLC growth and its prognostic value. Unfortunately, its contribution in NSCLC metastasis
remains elusive. Here, netrin-1 had relatively high expression in NSCLC tissues and
cells, especially in high metastatic groups. Notably, netrin-1 overexpression aggravated
the malignant metastatic behavior of NSCLC cells, including cell invasion, migration,
and vasculogenic mimicry (VM), whereas netrin-1 depression reversely dampened the
metastatic potential. Mechanism analysis confirmed that elevation of netrin-1 induced
the typical morphological changes of epithelial-to-mesenchymal transition (EMT) and
increased the expression of EMT markers, including E-cadherin down-regulation and
N-cadherin up-regulation. Consistently, netrin-1 inhibition inversely antagonized
the occurrence of EMT. Moreover, netrin-1 also activated the oncogenic pathways of
PI3K/AKT and ERK signaling. More importantly, blocking these pathways with their antagonists
LY294002 or U0126 reversed the effects of netrin-1 overexpression on cell invasion,
migration, EMT, and VM formation. Collectively, the current data suggest that netrin-1
can act as a pro-metastatic factor in NSCLC by enhancing cell invasion, migration,
and VM via PI3K/AKT and ERK-mediated EMT process, thereby implicating netrin-1 as
a novel promising therapeutic target against aggressive NSCLC.
</p>